ProPhase Labs, Inc. (PRPH)
| Market Cap | 13.90M |
| Revenue (ttm) | 12.75M |
| Net Income (ttm) | -27.76M |
| Shares Out | 30.23M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,310,366 |
| Open | 0.5000 |
| Previous Close | 0.4800 |
| Day's Range | 0.4510 - 0.5200 |
| 52-Week Range | 0.2200 - 7.4800 |
| Beta | -0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2025 |
About PRPH
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, includi... [Read more]
Financial Performance
Financial StatementsNews
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced...
ProPhase Labs to Present at the Investor Summit Virtual on March 11
GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announce...
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
New York, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase La...
ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
Company Announces Ongoing Strategic Cost Cutting to Focus Resources on new DTC Marketing Initiatives to Drive Growth and Profitability Dispels rumors of an Investment Bank initiating a Capital Raise G...
ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase L...
ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced...
ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Execu...
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that t...
ProPhase Labs Announces Pricing of Public Offering of Common Stock
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pr...
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event
GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that ...
ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Execut...
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call ho...
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress
PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Crea...
ProPhase Labs: Hidden Gem With An AI Kicker
ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to le...
ProPhase Labs, Inc. (PRPH) Q1 2024 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2024 Earnings Conference Call May 9, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive ...
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and...
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap...
ProPhase Labs Unveils Project ZenQ-AI
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development.
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its p...
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced th...
ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript
ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript
ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenu...
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted...
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, g...